Bayer's Silent Pharmaceutical Revolution: How Pipeline Wins Outpaced the Legal Headlines

Bayer stock gains 78% as Supreme Court ruling cuts Roundup liabilities, while pharma pipeline with Asundexian and Ambelvist drives growth amidst litigation and debt challenges.

Bayer’s stock has clocked a 78% gain over the past twelve months, with a blistering 24% surge in the last seven days alone. The immediate trigger — the US Supreme Court’s 7-to-2 ruling on June 25, 2026, that effectively gutted thousands of Roundup “failure-to-warn” claims — is well known. But what is keeping that rally alive runs far deeper than any single legal victory. Behind the headlines, the pharmaceutical division is quietly rewriting its own script.

The company’s most urgent commercial problem is plain: revenue from the blockbuster anticoagulant Xarelto cratered by a third in 2025, dropping to $2.6 billion. Bayer is racing to replace it with the oral Factor XIa inhibitor Asundexian. The European Medicines Agency is already reviewing the drug under a centralised procedure, and the US Food and Drug Administration has granted an accelerated review based on a global Phase III trial involving more than 12,000 participants. Bayer was the first to file a European application for this new drug class, stealing a march on the rival Milvexian from Bristol Myers Squibb and Johnson & Johnson. A regulatory decision is expected in the autumn.

Beyond Asundexian, the pipeline is churning out milestones. On June 15, the FDA approved Ambelvist, an MRI contrast agent that claims the lowest dosage of any product in its US-market class. In oncology, new data on the prostate cancer drug Nubeqa presented at the 2026 ASCO annual meeting showed cognitive preservation advantages over competitors. The company is aiming for mid-single-digit percentage growth in its pharma division from 2027 onward and an operating margin of roughly 30% by 2030.

To turbocharge early-stage research, Bayer has struck a partnership with the biotech firm Iambic Therapeutics, deploying artificial intelligence to crack difficult molecular targets. The goal is to boost R&D productivity by 40% by the turn of the decade — a concrete bet on the next generation of drug discovery, not just a PR exercise.

Yet the balance sheet remains a heavy counterweight. CFO Wolfgang Nickl has flagged a cash outflow of roughly €5 billion this year for litigation, dragging free cash flow to as much as €2.5 billion in the red. Net debt stands at about €32.5 billion. The Supreme Court’s ruling slashed the legal overhang, but the company still carries a €7.25 billion settlement proposal in Missouri that has yet to receive final court approval. Jefferies analyst Michael Leuchten, who raised his target from €40 to €46, explicitly warns that a collapse of that deal could swiftly erase a chunk of the recent gains.

Wall Street’s broader reaction has been emphatic. Goldman Sachs lifted its price target to €55, calling the decision “a step towards ending a decade of legal uncertainty.” UBS set a fair value of €52, while JPMorgan and Barclays both settled on €50, arguing the “Monsanto discount” is no longer justified.

On the charts, the stock trades at €46.83 — about 7% below its 52-week high of €49.93 — but the 14-day relative strength index has climbed to nearly 81, deep in overbought territory. That makes a near-term pullback historically likely, especially given that the shares now sit 28% above their long-term average.

Bayer has built a dual engine: a legal reversal that clears the horizon and a pharmaceutical pipeline that promises to fill the Xarelto gap. The real test will come in 2027, when the pharma division must deliver the growth the market is already pricing in. Until then, the company’s story remains one of two transformations running in parallel — one public and sudden, the other deliberate and largely out of the headlines.